-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎ WuXi AppTec content team editor September 13, 2021, Legend Biotech announced that based on the IND application approved by the US FDA, it will start a phase 1 clinical trial of the cell therapy LB1901 under investigation for the treatment of adult relapse/ Refractory peripheral T-cell lymphoma (PTCL), or cutaneous T-cell lymphoma (CTCL)
.
LB1901 is an autologous CD4 targeting chimeric antigen receptor T cell (CAR-T) therapy under development, which can specifically bind to CD4
.
CD4 is a membrane glycoprotein expressed in most T-cell lymphoma (TCL) subtypes
.
TCL is a group of heterogeneous lymphoid malignancies
.
PTCL includes uncommon and usually aggressive subtypes, with a 5-year overall survival of only 39%
.
CTCL is a group of T cell malignancies that mainly occur in the skin
.
Despite the current treatment options, a large proportion of patients with PTCL or CTCL are still prone to relapse
.
Patients with relapsed/refractory PTCL and CTCL still have highly unmet medical needs
.
This open-label, multi-center phase 1 trial will evaluate the safety and tolerability of LB1901 in patients with relapsed/refractory PTCL or relapsed/refractory CTCL expressing CD4, and determine the optimal dose
.
Image source: Legendary Bio's official website "We are excited about the potential of LB1901, and we look forward to further evaluating the safety and tolerability of LB1901
.
Determining the optimal dose for follow-up evaluation is one of the key goals of this trial,” said Dr.
Lida Pacaud, vice president of clinical development at Legend Bio.
“Patients with relapsed/refractory TCL have significant unmet medical needs.
This trial will provide information on Important information about the potential of CAR-T therapy to treat this disease
.
"Reference: [1] Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma.
Retrieved September 13, 2021, from https:// .
com/news/home/20210913005052/en Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views in the text do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's position Support or oppose the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
.
LB1901 is an autologous CD4 targeting chimeric antigen receptor T cell (CAR-T) therapy under development, which can specifically bind to CD4
.
CD4 is a membrane glycoprotein expressed in most T-cell lymphoma (TCL) subtypes
.
TCL is a group of heterogeneous lymphoid malignancies
.
PTCL includes uncommon and usually aggressive subtypes, with a 5-year overall survival of only 39%
.
CTCL is a group of T cell malignancies that mainly occur in the skin
.
Despite the current treatment options, a large proportion of patients with PTCL or CTCL are still prone to relapse
.
Patients with relapsed/refractory PTCL and CTCL still have highly unmet medical needs
.
This open-label, multi-center phase 1 trial will evaluate the safety and tolerability of LB1901 in patients with relapsed/refractory PTCL or relapsed/refractory CTCL expressing CD4, and determine the optimal dose
.
Image source: Legendary Bio's official website "We are excited about the potential of LB1901, and we look forward to further evaluating the safety and tolerability of LB1901
.
Determining the optimal dose for follow-up evaluation is one of the key goals of this trial,” said Dr.
Lida Pacaud, vice president of clinical development at Legend Bio.
“Patients with relapsed/refractory TCL have significant unmet medical needs.
This trial will provide information on Important information about the potential of CAR-T therapy to treat this disease
.
"Reference: [1] Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma.
Retrieved September 13, 2021, from https:// .
com/news/home/20210913005052/en Disclaimer: WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The views in the text do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's position Support or oppose the views
in the
article .
This article is not a treatment plan recommendation
.
If you need treatment plan guidance, please go to a regular hospital
.
